TABLE 2.
Baseline Demographic and Clinical Characteristics Before and After Weighting, IXE Versus ADA
| Baseline Patient Characteristics | Before Weighting | After Weighting | ||||
|---|---|---|---|---|---|---|
| IXE | ADA | StdDiffa | IXE | ADA | StdDiffa | |
| n = 388 | n = 2,578 | |||||
| Age, years, mean (SD) | 49.4 (11.3) | 47.0 (12.7) | 0.200 | 47.7 (12.5) | 47.7 (12.9) | 0.004 |
| Male, % | 55.4 | 56.1 | 0.013 | 56.2 | 56.5 | 0.006 |
| Commercial payer, % | 93.8 | 94.1 | 0.014 | 93.9 | 92.7 | 0.051 |
| Insurance plan type, % | 0.234 | 0.108 | ||||
| Comprehensive/indemnity | 2.6 | 6.2 | 5.1 | 5.7 | ||
| HMO | 6.7 | 7.1 | 6.3 | 6.9 | ||
| POS/POS with capitation | 11.6 | 7.3 | 7.7 | 9.3 | ||
| PPO | 59.0 | 57.3 | 60.1 | 56.6 | ||
| Other (e.g., CDHP, HDHP, EPO) | 19.8 | 21.5 | 19.7 | 21.0 | ||
| Unknown | 0.3 | 0.6 | 1.1 | 0.5 | ||
| Geographic region, % | 0.155 | 0.087 | ||||
| Northeast | 14.4 | 15.6 | 15.4 | 15.1 | ||
| North Central | 16.5 | 20.7 | 19.3 | 19.8 | ||
| South | 59.3 | 53.1 | 56.1 | 54.7 | ||
| West | 9.8 | 10.4 | 9.2 | 10.1 | ||
| Unknown | 0.0 | 0.3 | 0.0 | 0.3 | ||
| Deyo-Charlson Comorbidity Index score, mean (SD) | 0.5 (1.2) | 0.4 (1.0) | 0.095 | 0.4 (1.1) | 0.4 (1.0) | 0.014 |
| Comorbid conditions, % | ||||||
| Anxiety | 11.1 | 12.7 | 0.050 | 11.8 | 12.3 | 0.014 |
| Coronary heart disease | 6.7 | 4.2 | 0.109 | 3.9 | 4.4 | 0.027 |
| Depression | 13.4 | 10.4 | 0.094 | 12.2 | 10.6 | 0.049 |
| Diabetes | 18.6 | 13.5 | 0.139 | 14.5 | 15.2 | 0.021 |
| Hyperlipidemia | 34.3 | 29.0 | 0.113 | 31.5 | 29.2 | 0.051 |
| Hypertension | 39.2 | 33.1 | 0.127 | 33.7 | 33.4 | 0.008 |
| Multiple sclerosis | 0 | 0.1 | N/A | 0 | 0.1 | N/A |
| Obesity | 24.2 | 18.5 | 0.141 | 15.8 | 18.8 | 0.078 |
| Osteoarthritis | 9.5 | 8.9 | 0.021 | 9.1 | 8.9 | 0.008 |
| Other autoimmune disorders | 3.9 | 2.4 | 0.081 | 2.6 | 2.6 | 0.003 |
| Peripheral vascular disease | 1.0 | 1.4 | 0.030 | 1.1 | 1.3 | 0.016 |
| Sleep apnea | 13.1 | 8.5 | 0.149 | 8.9 | 9.0 | 0.005 |
| PsO treatments | ||||||
| Any biologics, % | 69.1 | 41.5 | 0.578 | 43.8 | 46.0 | 0.044 |
| Unique biologics, n, mean (SD) | 0.8 (0.6) | 0.4 (0.5) | 0.658 | 5.0 (0.5) | 0.5 (0.5) | 0.038 |
| Any systemic agents/targeted oral therapies, % | 59.3 | 52.1 | 0.145 | 50.9 | 53.6 | 0.056 |
| Any topical agents, % | 75.3 | 71.8 | 0.078 | 72.5 | 72.6 | 0.003 |
| Phototherapy or laser treatments, % | 8.0 | 6.7 | 0.051 | 5.7 | 6.7 | 0.042 |
| All-cause health care costb, USD, mean (SD) | 4,123 (3,871) | 1,977 (2,483) | 0.660 | 2,504 (3,406) | 2,399 (2,988) | 0.033 |
| PsO-specific health care costb, USD, mean (SD) | 3,130 (2,568) | 1,287 (1,551) | 0.869 | 1,578 (1,836) | 1,702 (2,308) | 0.059 |
aA standardized difference of less than 0.1 is considered well balanced.
bReported per patient per month.
ADA = adalimumab; CDHP = consumer-driven health plan; EPO = exclusive provider organization; HDHP = high-deductible health plan; HMO = health maintenance organization; IXE = ixekizumab; POS = point-of-service; PPO = preferred provider organization; SD = standard deviation; StdDiff = standardized difference.